GO:0043276 anoikis: Detachment-Induced Cell Death, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• Anoikis (GO:0043276) is apoptosis triggered by inadequate or inappropriate adherence to substrate, such as after disruption of interactions between normal epithelial cells and the extracellular matrix.
• Anoikis is a critical tumor-suppressive barrier: epithelial cells that detach from the extracellular matrix normally die, and resistance to anoikis is a hallmark of metastatic cancer cells.
• Anoikis resistance enables cancer cells to survive in circulation, colonize distant organs, and form metastases, making it a major therapeutic target.
• Multiple signaling pathways regulate anoikis, including integrin-mediated adhesion, growth factor receptor signaling, lipid signaling, and apoptotic effectors such as BCL-2 family proteins.
• Anoikis is studied using detachment assays, live-cell imaging, RNA-seq, proteomics, and CRISPR-based knockout or knock-in models to dissect causal genes.
• EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression cell models and library screening to accelerate anoikis research.
Description
Anoikis is a specialized form of programmed cell death that occurs when cells lose proper attachment to the extracellular matrix (ECM) or adhere inappropriately to a substrate. This process is essential for normal tissue homeostasis, development, and the prevention of ectopic cell growth. The term was coined to describe the detachment-induced apoptosis observed in epithelial cells, and it has since become a central concept in cancer biology, where resistance to anoikis is recognized as a key step in metastasis. Mechanistically, anoikis is triggered when integrin-mediated adhesion is disrupted, leading to changes in cytoskeletal organization, mitochondrial function, and activation of pro-apoptotic BCL-2 family proteins. Cancer cells often acquire anoikis resistance through alterations in signaling pathways, gene expression, and metabolic reprogramming, allowing them to survive in the absence of ECM attachment and to colonize distant organs. Understanding the molecular players and regulatory networks of anoikis is therefore critical for developing anti-metastatic therapies. This article provides a research-grade overview of GO:0043276, covering its definition, core mechanisms, key genes, disease relevance, and experimental methods. It is designed for researchers seeking to study anoikis using CRISPR-based models and functional genomics approaches.
anoikis At A Glance
| GO ID | GO:0043276 |
|---|---|
| GO term | anoikis |
| Ontology | biological_process |
| Synonym | detachment induced cell death; suspension induced apoptosis |
| Major function | Apoptosis triggered by inadequate or inappropriate adherence to substrate, such as after disruption of interactions between normal epithelial cells and the extracellular matrix |
| Related processes | Apoptosis, cell adhesion, extracellular matrix organization, metastasis |
| Disease relevance | Cancer metastasis, anoikis resistance, prostate cancer bone metastasis, gastric cancer, colorectal cancer liver metastasis |
| Research methods | Detachment assays, live-cell imaging, RNA-seq, proteomics, CRISPR knockout/knock-in models |
What Is GO:0043276?
According to the Gene Ontology, anoikis (GO:0043276) is defined as apoptosis triggered by inadequate or inappropriate adherence to substrate, for example after disruption of the interactions between normal epithelial cells and the extracellular matrix. It is a biological process that represents a specific form of programmed cell death distinct from other apoptotic triggers, and it is synonymous with detachment-induced cell death and suspension-induced apoptosis.
Why Is anoikis Important in Cell Biology?
Anoikis is fundamentally important because it acts as a natural barrier against the survival and dissemination of detached cells, and its dysregulation is a hallmark of cancer progression and metastasis. Loss of anoikis sensitivity allows cancer cells to survive after detachment from the primary tumor, travel through the bloodstream or lymphatic system, and establish secondary tumors in distant organs. Consequently, anoikis resistance is a major focus of cancer research, with studies identifying specific genes and pathways that can be targeted to restore this cell death program.
• Anoikis prevents detached epithelial cells from surviving in inappropriate locations, thereby maintaining tissue architecture.
• Resistance to anoikis is a critical step in the metastatic cascade, enabling cancer cells to survive in circulation and colonize distant organs.
• Anoikis resistance has been documented in multiple cancers, including prostate cancer, gastric cancer, and colorectal cancer liver metastasis.
• Targeting anoikis resistance is emerging as a therapeutic strategy to inhibit metastasis and improve patient outcomes.
• Lipid signaling pathways, including sphingolipid and phospholipid metabolism, modulate anoikis sensitivity in cancer cells.
• Anoikis is involved in phenotypic reprogramming of the tumor microenvironment, influencing cancer cell plasticity and stromal interactions.
• Studying anoikis helps identify biomarkers for metastatic potential and therapeutic vulnerabilities.
• CRISPR-based models enable precise dissection of genes that regulate anoikis, accelerating target discovery.
What Happens During anoikis?
Loss of ECM Attachment and Integrin Signaling
In simple terms: When cells lose their grip on the extracellular matrix, they stop receiving survival signals and start dying.
Anoikis is initiated when normal epithelial cells detach from the extracellular matrix (ECM), disrupting integrin-mediated adhesion. Integrins normally transmit survival signals through focal adhesion kinase (FAK) and SRC family kinases; loss of attachment leads to reduced FAK phosphorylation and decreased pro-survival signaling. This detachment also alters cytoskeletal dynamics and causes changes in cell shape that contribute to the apoptotic trigger.
Mitochondrial Dysfunction and BCL-2 Family Activation
In simple terms: Detached cells activate the mitochondrial death machinery, which punches holes in mitochondria and commits the cell to apoptosis.
Following detachment, pro-apoptotic BCL-2 family proteins such as BAX and BAK become activated, leading to mitochondrial outer membrane permeabilization and release of cytochrome c. This process is regulated by the balance between pro-apoptotic and anti-apoptotic BCL-2 family members, and anoikis resistance often involves upregulation of anti-apoptotic proteins like BCL-2 or BCL-XL. The intrinsic apoptotic pathway is thus a central executioner of anoikis.
Caspase Activation and Apoptotic Execution
In simple terms: Once the death signal is triggered, caspases are activated and dismantle the cell.
Cytochrome c release leads to apoptosome formation and activation of caspase-9, which in turn activates executioner caspases-3 and -7. These caspases cleave cellular substrates, resulting in the morphological hallmarks of apoptosis such as cell shrinkage, membrane blebbing, and DNA fragmentation. In anoikis-resistant cancer cells, caspase activation is often suppressed through inhibitors of apoptosis (IAPs) or other mechanisms.
Metabolic and Signaling Adaptations in Anoikis Resistance
In simple terms: Cancer cells can rewire their metabolism and signaling to survive without attachment.
Anoikis-resistant cancer cells often exhibit altered lipid signaling, including changes in sphingosine-1-phosphate and ceramide levels, which promote survival. They may also activate growth factor receptor pathways, such as EGFR or IGF-1R, and downstream PI3K/AKT and MAPK signaling to counteract apoptotic signals. Additionally, phenotypic reprogramming of the tumor microenvironment can support anoikis resistance through stromal-derived factors.
Detachment-Induced Autophagy and Other Cell Fates
In simple terms: Detached cells can also activate autophagy or other death programs that interact with anoikis.
Depending on cellular context, detachment can induce autophagy, which may either promote survival or contribute to cell death. Cross-talk between autophagy and apoptosis influences the outcome of anoikis, and cancer cells may exploit autophagy to survive detachment. Other regulated cell death modalities, such as NETosis, have been linked to anoikis in specific contexts like colorectal cancer liver metastasis.
Key Genes Involved in GO:0043276 anoikis
The following genes and proteins are central to anoikis regulation, based on published literature, and represent key targets for CRISPR-based functional studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Tumor suppressor that induces apoptosis in response to detachment and DNA damage | Loss of TP53 promotes anoikis resistance and metastasis |
| BCL2 | Anti-apoptotic protein that inhibits mitochondrial outer membrane permeabilization | Overexpression confers anoikis resistance in multiple cancers |
| BAX | Pro-apoptotic effector that permeabilizes mitochondria during anoikis | BAX activation is required for detachment-induced apoptosis |
| BAK | Pro-apoptotic effector that cooperates with BAX in mitochondrial permeabilization | BAK loss reduces anoikis sensitivity |
| PTK2 (FAK) | Focal adhesion kinase that transmits integrin-mediated survival signals | FAK inhibition sensitizes cancer cells to anoikis |
| SRC | Non-receptor tyrosine kinase that promotes survival signaling downstream of integrins | SRC activation contributes to anoikis resistance |
| PIK3CA | Catalytic subunit of PI3K that activates AKT survival signaling | PI3K/AKT pathway activation drives anoikis resistance |
| AKT1 | Serine/threonine kinase that promotes cell survival and inhibits apoptosis | AKT1 activation is a common mechanism of anoikis resistance |
| MAPK1 (ERK2) | Kinase in the MAPK pathway that transduces growth factor signals | ERK signaling supports survival during detachment |
| TUBB3 | Beta-tubulin isotype involved in microtubule dynamics and anoikis resistance | TUBB3 targeting suppresses anoikis resistance and bone metastasis in prostate cancer |
| EGFR | Growth factor receptor that activates pro-survival pathways | EGFR signaling promotes anoikis resistance |
| IGF1R | Insulin-like growth factor receptor that activates PI3K/AKT | IGF1R signaling contributes to anoikis resistance |
| SPHK1 | Sphingosine kinase 1 that produces sphingosine-1-phosphate | Lipid signaling via SPHK1 modulates anoikis |
| CASP3 | Executioner caspase that carries out apoptosis | CASP3 activation is a hallmark of anoikis |
| CASP9 | Initiator caspase activated by cytochrome c release | CASP9 activation is required for anoikis |
| CDH1 (E-cadherin) | Cell-cell adhesion molecule that influences detachment and anoikis sensitivity | Loss of E-cadherin is associated with anoikis resistance |
| VIM | Vimentin, a mesenchymal marker linked to anoikis resistance | Vimentin expression correlates with metastatic potential |
| FN1 | Fibronectin, an ECM protein that supports adhesion and survival | FN1 interactions modulate anoikis |
How Is anoikis Regulated?
Anoikis is regulated by a complex network of signaling pathways. Integrin-mediated adhesion to the ECM provides survival signals through FAK and SRC, and loss of these signals triggers anoikis. Growth factor receptor pathways, including EGFR, IGF1R, and downstream PI3K/AKT and MAPK cascades, can suppress anoikis and promote resistance. Lipid signaling, particularly sphingosine-1-phosphate and ceramide balance, also modulates anoikis sensitivity. Additionally, the tumor microenvironment and phenotypic reprogramming of stromal cells can influence anoikis resistance through secreted factors and cell-cell interactions. Targeting these regulatory nodes, such as TUBB3, has been shown to suppress anoikis resistance and metastasis in preclinical models.
anoikis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TUBB3 | Prostate cancer bone metastasis and anoikis resistance | CRISPR knockout in prostate cancer cell lines, followed by detachment assays |
| TP53 | Loss promotes anoikis resistance and metastasis across cancers | TP53 knockout or point mutation in epithelial cancer cells |
| BCL2 | Overexpression confers anoikis resistance | BCL2 overexpression cell model to test anoikis sensitivity |
| PTK2 (FAK) | FAK signaling supports survival during detachment | FAK knockout or kinase-dead knock-in in cancer cells |
| SPHK1 | Lipid signaling modulates anoikis in cancer | SPHK1 knockout or overexpression in cancer cell lines |
Anoikis Resistance in Cancer Metastasis
Anoikis resistance is a critical enabling characteristic of metastatic cancer cells, allowing them to survive after detachment from the primary tumor and to colonize distant organs. In prostate cancer, targeting TUBB3 suppresses anoikis resistance and bone metastasis, highlighting a potential therapeutic strategy. In gastric cancer, comprehensive reviews have documented multiple mechanisms of anoikis resistance that contribute to disease progression. Colorectal cancer liver metastasis involves complex interactions between anoikis and other processes such as NETosis.
Anoikis in the Tumor Microenvironment
The tumor microenvironment plays a key role in modulating anoikis. Phenotypic reprogramming of the prostate tumor microenvironment can promote anoikis resistance through changes in stromal cells and secreted factors. Lipid signaling within the microenvironment also influences anoikis sensitivity, with sphingolipid metabolites acting as survival cues. Understanding these interactions is essential for developing therapies that target the microenvironment to restore anoikis.
Therapeutic Targeting of Anoikis Resistance
Targeting anoikis resistance is an emerging strategy for cancer therapy. Approaches include inhibiting pro-survival kinases such as FAK, SRC, PI3K, and AKT, or modulating BCL-2 family proteins to lower the apoptotic threshold. TUBB3 inhibition has shown promise in suppressing anoikis resistance and bone metastasis in prostate cancer. Further research using CRISPR screens and functional genomics is expected to identify new targets for restoring anoikis in metastatic cells.
From anoikis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene cause anoikis resistance? | CRISPR knockout cell line followed by detachment assay |
| Does a specific point mutation in a gene alter anoikis sensitivity? | CRISPR point-mutation knock-in cell line |
| Does a gene fusion or tag affect anoikis signaling? | CRISPR knock-in of tag or reporter |
| Does overexpression of a survival gene confer anoikis resistance? | CRISPR overexpression cell model |
| Which genes are essential for anoikis across the genome? | CRISPR library screening under detachment conditions |
| How does a gene affect metastatic colonization in vivo? | Xenograft or metastasis mouse models using edited cells |
How to Study the anoikis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Detachment assay (poly-HEMA) | Cell viability and apoptosis after loss of adhesion | Assessing anoikis sensitivity |
| Live-cell imaging | Real-time caspase activation, mitochondrial changes | Visualizing anoikis dynamics |
| RNA-seq | Transcriptional changes during detachment | Identifying survival pathways |
| Proteomics | Protein expression and modification changes | Discovering signaling nodes |
| CRISPR knockout screen | Genes required for anoikis or resistance | Genome-wide target discovery |
| CRISPR activation screen | Genes whose overexpression confers resistance | Identifying survival factors |
| Xenograft/metastasis model | Metastatic colonization in vivo | Validating targets |
| Lipidomics | Sphingolipid and phospholipid profiles | Studying lipid signaling in anoikis |
Detachment Assays and Live-Cell Imaging
Anoikis is commonly studied using detachment assays, such as culturing cells on poly-HEMA-coated plates to prevent adhesion, followed by viability measurements. Live-cell imaging can track morphological changes, caspase activation, and mitochondrial dynamics in real time. These methods are foundational for assessing anoikis sensitivity and resistance in cancer cells.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can identify gene expression and protein changes during anoikis or in anoikis-resistant cells. Comparative analyses between attached and detached cells reveal pathways that promote survival or death. These approaches have been used to uncover lipid signaling and metabolic adaptations in anoikis resistance.
CRISPR Screens for Anoikis Regulators
Genome-wide CRISPR knockout or activation screens under detachment conditions can systematically identify genes that modulate anoikis. Such screens have the power to discover novel therapeutic targets and to validate known pathways. Hits can be further studied using individual knockout or knock-in models.
In Vivo Metastasis Models
To study the role of anoikis in metastasis, edited cancer cells can be injected into mice via tail vein or orthotopic routes, and metastatic burden assessed. These models help determine whether a gene of interest affects survival in circulation and colonization of distant organs. They are essential for translating in vitro findings to potential therapies.
How CRISPR Can Be Used to Study GO:0043276 anoikis
Knockout
CRISPR knockout is used to delete candidate anoikis regulators and test whether their loss alters detachment-induced cell death. For example, knocking out TUBB3 in prostate cancer cells can suppress anoikis resistance and reduce bone metastasis in vivo. Knockout models are essential for establishing causality in anoikis pathways.
Point Mutation
CRISPR point mutation allows introduction of specific amino acid changes to study protein function in anoikis. For instance, mutating phosphorylation sites in FAK or AKT can reveal their role in survival signaling during detachment. This approach provides mechanistic insights beyond simple knockout.
Knock-in
Knock-in of tags, reporters, or mutant alleles enables tracking of proteins during anoikis. Fluorescent tagging of BAX or BAK can visualize their activation and localization upon detachment. Knock-in of disease-associated mutations can model their impact on anoikis sensitivity.
Overexpression
CRISPR overexpression models are used to test whether increased levels of a gene confer anoikis resistance. Overexpressing BCL2 or SPHK1 can protect cells from detachment-induced apoptosis. These models help identify survival factors that could be targeted therapeutically.
How EDITGENE Supports anoikis Research
Researchers studying anoikis-related genes often need to determine whether a candidate gene is causally involved in detachment-induced cell death or resistance. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely edited cell models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for anoikis research.
Frequently Asked Questions About anoikis
What is anoikis?
Anoikis is a form of programmed cell death that occurs when cells detach from the extracellular matrix or adhere inappropriately to a substrate, as defined by GO:0043276.
What genes are involved in anoikis?
Key genes include TP53, BCL2, BAX, BAK, PTK2 (FAK), SRC, PIK3CA, AKT1, MAPK1, TUBB3, EGFR, IGF1R, SPHK1, CASP3, and CASP9, among others.
How is anoikis resistance related to cancer?
Anoikis resistance allows cancer cells to survive after detachment from the primary tumor, facilitating metastasis to distant organs.
What is the role of TUBB3 in anoikis?
TUBB3 is a beta-tubulin isotype that contributes to anoikis resistance; targeting TUBB3 suppresses anoikis resistance and bone metastasis in prostate cancer.
How can I study anoikis in the lab?
Common methods include detachment assays, live-cell imaging, RNA-seq, proteomics, and CRISPR screens.
What is the difference between anoikis and apoptosis?
Anoikis is a specific type of apoptosis triggered by loss of attachment, whereas apoptosis can be induced by many other stimuli.
Which signaling pathways regulate anoikis?
Integrin/FAK/SRC, PI3K/AKT, MAPK, and lipid signaling pathways are major regulators of anoikis.
Can CRISPR be used to study anoikis?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to dissect gene function in anoikis.
What diseases are associated with anoikis dysregulation?
Cancer metastasis is the most prominent, including prostate cancer, gastric cancer, and colorectal cancer liver metastasis.
How does the tumor microenvironment affect anoikis?
The tumor microenvironment can promote anoikis resistance through stromal cell reprogramming and secreted factors.
Conclusion
Anoikis (GO:0043276) is a fundamental biological process that safeguards tissue homeostasis by eliminating cells that lose proper matrix attachment. Its dysregulation is a key driver of cancer metastasis, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and functional genomics are accelerating the discovery of anoikis regulators and resistance mechanisms. Continued research into the molecular networks of anoikis will likely yield new strategies to prevent or treat metastatic disease.
References
- 1. Wang Y et al.. 2024. Targeting anoikis resistance as a strategy for cancer therapy.. Drug Resist Updat 75:101099 PMID: 38850692
- 2. Zhang R et al.. 2025. Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives.. Biochim Biophys Acta Rev Cancer 1880(5):189401 PMID: 40744394
- 3. Gilmore AP. 2005. Anoikis.. Cell Death Differ 12 Suppl 2:1473-7 PMID: 16247493
- 4. Frisch SM et al.. 2025. Anoikis resistance and cancer.. BMC Cancer 25(1):1764 PMID: 41239272
- 5. Dong B et al.. 2024. Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer.. Adv Healthc Mater 13(28):e2400673 PMID: 38809199
- 6. Raeisi M et al.. 2022. Anoikis in cancer: The role of lipid signaling.. Cell Biol Int 46(11):1717-1728 PMID: 36030535
- 7. Nepali PR et al.. 2023. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.. Front Endocrinol (Lausanne) 14:1160267 PMID: 37091854
- 8. D'Amore T et al.. 2025. Anoikis resistance in gastric cancer: a comprehensive review.. Cell Death Dis 16(1):528 PMID: 40664635
